Introduction to a How I Treat series on myeloproliferative neoplasms

The biologic, clinical, and molecular heterogeneity of myeloproliferative neoplasms (MPNs), as well as the unique treatment goals of individuals, often lead to a melding of data-driven algorithms with personalized care approaches informed by shared decision-making between patients and their physicians. Associate Editor Jason Gotlib introduces this How I Treat series commissioned to bring readers up to date with leading-edge practice related to several MPNs. In each, experts illustrate their points through consideration of several real-world cases. McMullin and Harrison tackle low-risk polycythemia vera, while 2 articles focus on myelofibrosis: Masarova and Chifotides discuss how to individualize selection of Janus kinase inhibitor therapy, and Jain and Gerds address the common problem of anemia in this disease. Deepti H. Radia discusses how to approach the challenges of systemic mastocytosis with an associated hematologic neoplasm in the modern KIT inhibitor era. Some MPNs are very rare, such as the collection of myeloid/lymphoid neoplasms driven by tyrosine kinase gene fusions, and Reiter and colleagues discuss the variable prognoses of these diseases and best available treatment options. Across all MPNs, thrombosis is a major problem, so the final article by Guy et al discusses their preferred cytoreductive, antiplatelet, and antithrombotic strategies for preventing arterial and venous thrombosis occurrence and recurrence.